Citigroup Inc Terns Pharmaceuticals, Inc. Transaction History
Citigroup Inc
- $196 Billion
- Q2 2025
A detailed history of Citigroup Inc transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 38,274 shares of TERN stock, worth $249,929. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,274
Previous 54,182
29.36%
Holding current value
$249,929
Previous $149,000
4.7%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding TERN
# of Institutions
134Shares Held
84.3MCall Options Held
173KPut Options Held
89.5K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$53.3 Million2.36% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$49.4 Million1.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$48.9 Million0.99% of portfolio
-
Morgan Stanley New York, NY7.25MShares$47.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$45 Million5.45% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $246M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...